Hikma Pharmaceuticals Share Price (HIK)

982.00 -13.00 (-1.31%) delayed: 7:04AM GMT
Bid price 982.00 Open price 990.40
Ask price 982.20 Prev close 982.00
High price 1,005.00 Spread 0.02%
Low price 981.80 Volume 765,477

Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.

Hikma Pharmaceuticals Share Price Chart

Advanced Charts >>

Register now for FREE Hikma Pharmaceuticals share price charts

Hikma Pharmaceuticals Share Price Information

Name Hikma Pharmaceuticals Epic HIK
Sector Pharmaceuticals & Biotechnology ISIN GB00B0LCW083
Activites Hikma Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'njectables, Generics and Branded, based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million. Index FTSE 250

Hikma Pharmaceuticals Key Numbers

Latest Share Price (p) 982.00 Net Gearing (%) 41.19
Market Capitalisation (£m) 2,394.76 Gross Gearing (%) 44.74
Shares in issue (m) 240.68 Debt Ratio 30.02
P/E Ratio 14.96 Debt-to-Equity Ratio 0.53
Total dividends per share (p) 33.00 Assets / Equity Ratio 1.81
Dividend Yield (%) 2.13 Price to book value 0.99
Dividend cover (x) 2.02 ROCE (%) 6.10
Earning per share (p) 66.50 EPS Growth (%) -47.47
52 week high / low 2,346.00 / 906.50 DPS Growth (%) 3.13

Hikma Pharmaceuticals Director Deals

Dec.Date Type Director Pos No. of Shares
31/05/2017 TIN Mazen Darwazah ED 38,088
31/05/2017 TIN Said Darwazah CH 52,164
15/05/2017 TIN Mazen Darwazah ED 30,000
15/05/2017 TIN Said Darwazah CH 41,000
20/12/2016 BUY Ali Al-Husry NED 140,730

More Hikma Pharmaceuticals Director Deals >>

Hikma Pharmaceuticals Company News

17:22 17/01/2018

Holding(s) in Company

RNS Number : 1912C Hikma Pharmaceuticals Plc 17 January 2018   TR-1: S tandard form for notification of major holdings   LONDON, 17 January 2018 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) , the fast-growing...

09:39 15/01/2018

Hikma appoints chief scientific officer and head of R&D

Hikma Pharmaceuticals has appointed Surendera Tyagi as group chief scientific officer and global head of research and development. Dr Tyagi will focus on the group's non-injectables business during the first year and will become a member of Hikma's executive committee. Tyagi joins from...

08:00 15/01/2018

Hikma Appoints Dr. Surendera Tyagi

RNS Number : 8062B Hikma Pharmaceuticals Plc 15 January 2018       PRESS RELEASE   Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D   London, 15 January 2018   - Hikma Pharmaceuticals PLC...

More Hikma Pharmaceuticals Company News >>

Register now for FREE Hikma Pharmaceuticals company news

Hikma Pharmaceuticals Share Price Discussions

more than 1 year ago

Hikma Pharmaceuticals (HIK)

Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...

Register now for FREE Hikma Pharmaceuticals share price discussions